Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 3/20 | 0.32 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10440065 | 0.81 | PNP (0.35) | NR1I2ALBPDE4DPNP | |
| SCHEMBL8718098 | 0.74 | DNMT1 (0.52) | PDE4DPNP | |
| SCHEMBL14743922 | 0.72 | ADORA3 (0.48) | — | |
| SCHEMBL132926 | 0.71 | PNP (0.54) | PNP | |
| SCHEMBL2185987 | 0.71 | PNP (0.54) | PNP | |
| SCHEMBL375987 | 0.71 | PNP (0.54) | PNP | |
| SCHEMBL10814753 | 0.71 | PNP (0.54) | PNP | |
| SCHEMBL10496354 | 0.71 | PNP (0.54) | PNP | |
| SCHEMBL132928 | 0.71 | PNP (0.54) | PNP | |
| SCHEMBL10814776 | 0.71 | PNP (0.54) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050196379-A1 | Combination therapies with L-FMAU for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-0366385-A1 | Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050196379-A1 | Combination therapies with L-FMAU for the treatment of hepatitis B virus infection | IFNG, OAT, EIF2AK2 | NR1I2 2283/4885ALB 855/4885PDE4D 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.